 Our amendment would reward companies who innovate their treatments to meet their patients needs, not Medicare reimbursement policies. Many of these patients suffer from rheumatoid arthritis and MS, two disabling conditions that can restrict mobility and make it very difficult to even get to a physician's office. As my colleagues know, I have spent the last 4 years working to end this outrageous disincentive in Medicare reimbursement policies.  